Clinical Efficacy of Sarpogrelate Hydrochloride in Preventing Restenosis after Femoral Artery Stent Implantation_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 DONGZhi-qiang ¹ , LIXue-yan ¹ , WANGZhong-chen ² , LIXi-chun ³ , LIZheng-mao ⁴

1. Department of Vascular Surgery, Daqing Oilfield General Hospital, Daqing 163000, Heilongjiang Province, China;
2. Department of Vascular Surgery, Daqing Longnan Hospital, Daqing 163000, Heilongjiang Province, China;
3. Department of Vascular Surgery, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar 161000, Heilongjiang Province, China;
4. Department of Vascular Surgery, The First People's Hospital of Qiqihar City, Qiqihar 161000, Heilongjiang Province, China;

Corresponding author：

DONGZhi-qiang, Email: dzq431978@163.com

Keywords：

Sarpogrelate hydrochloride; Femoral artery; Stent implantation; Restenosis; Prevention

DOI：

10.7507/1007-9424.20140172

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the clinical efficacy of sarpogrelate hydrochloride in preventing restenosis after femoral artery stent implantation. Methods Two hundreds and fifty-one cases of ischemic disease of lower extremity (286 affected limbs in total) who got treatment in our hospital were collected, and were divided into prevention group(125 cases with 146 affected limbs) and control group(126 cases with 140 affected limbs) according kinds of medicine. At the basement of medicine in control group, cases of prevention group got treatment of sarpogrelate hydrochloride in addition. Comparison of related indexed was performed by SPSS 17.0 software. Results Compared with before treatment in prevention group, only foot skin ulcer and gangrene score decreased(P<0.05), and there were no significant difference on other indexes included visual anafogue scales(VAS), intermittent claudication distance score, ankle brachial index (ABI), and vascular stenosis score(P>0.05). But in control group, compared with before treatment, foot skin ulcer and gangrene score and ABI value decreased(P<0.05), the VAS score, intermittent claudication distance score, and vascular stenosis score increased(P<0.05). There were significant difference on the difference between after treatment and before treatment of all 5 indexes(P<0.05), that the changed value of foot skin ulcer and gangrene score was higher in prevention group, but lower on other 4 indexes. There were no untoward effect happened during treatment. Conclusion Clinical effect of sarpogrelate hydrochloride in the prevention of restenosis of the femoral artery after stent implantation was significantly, and it can keep related indexes stable.

Citation： DONGZhi-qiang, LIXue-yan, WANGZhong-chen, LIXi-chun, LIZheng-mao. Clinical Efficacy of Sarpogrelate Hydrochloride in Preventing Restenosis after Femoral Artery Stent Implantation. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(6): 727-730. doi: 10.7507/1007-9424.20140172 Copy

1.	马震寰,杨镛,杨国凯,等.下肢动脉硬化闭塞症继发血栓形成治疗分析[J].中国普外基础与临床杂志, 2010, 17(3):275-277.
2.	王玉琦,史振宇.我国血管外科的现状与展望[J].中国普外基础与临床杂志, 2008, 15(6):387-389.
3.	Takasawa Y, Iijima R, Shiba M, et al.Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention[J].J Cardiol, 2010, 55(3):391-396.
4.	Norgren L, Hiatt WR, Dormandy JA, et al.Inter-society consensus for the management of peripheral arterial disease (TASC Ⅱ)[J].J Vasc Surg, 2007, 45 Suppl S:S5-S67.
5.	叶任高,陆再英.内科学[M].第6版.北京:人民卫生出版社, 2006:161-176.
6.	吴在德,吴肇汉.外科学[M].第6版.北京:人民卫生出版社, 2008:129-130.
7.	Edmonds ME, Foster AVM, Sanders LJ著.于德民,王鹏华译.糖尿病足诊治实践彩色图解[M].天津:天津科技翻译出版公司, 2006:14-16.
8.	Tuttle KR.Linking metalism and immunology:diabetic nephropathy is anin flammatorydisease[J].J Am Soe Nephrol, 2005, 16(6):1537-1538.
9.	张旭,吕豪,孙振学.银杏达莫联合前列腺素E1治疗糖尿病并发外周动脉疾病的临床研究[J].中国基层医药, 2010, 17(z2):81-82.
10.	Kroeze WK, Kristiansen K, Roth BL.Molecular biology of serotonin receptors structure and function at the molecular level[J].Curr Top Med Chem, 2002, 2(6):507-528.
11.	陈洁,叶志东,樊雪强,等.盐酸沙格雷酯用于股腘动脉长段闭塞介入治疗效果及安全性分析[J].心肺血管病杂志, 2013, 32(1):7-9.
12.	邵壮,顾洪斌,王志鸿,等.盐酸沙格雷酯对糖尿病伴膝下动脉病变球囊扩张成形术后疗效的影响[J].心肺血管病杂志, 2013, 32(1):16-19.

1. 马震寰,杨镛,杨国凯,等.下肢动脉硬化闭塞症继发血栓形成治疗分析[J].中国普外基础与临床杂志, 2010, 17(3):275-277.
2. 王玉琦,史振宇.我国血管外科的现状与展望[J].中国普外基础与临床杂志, 2008, 15(6):387-389.
3. Takasawa Y, Iijima R, Shiba M, et al.Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention[J].J Cardiol, 2010, 55(3):391-396.
4. Norgren L, Hiatt WR, Dormandy JA, et al.Inter-society consensus for the management of peripheral arterial disease (TASC Ⅱ)[J].J Vasc Surg, 2007, 45 Suppl S:S5-S67.
5. 叶任高,陆再英.内科学[M].第6版.北京:人民卫生出版社, 2006:161-176.
6. 吴在德,吴肇汉.外科学[M].第6版.北京:人民卫生出版社, 2008:129-130.
7. Edmonds ME, Foster AVM, Sanders LJ著.于德民,王鹏华译.糖尿病足诊治实践彩色图解[M].天津:天津科技翻译出版公司, 2006:14-16.
8. Tuttle KR.Linking metalism and immunology:diabetic nephropathy is anin flammatorydisease[J].J Am Soe Nephrol, 2005, 16(6):1537-1538.
9. 张旭,吕豪,孙振学.银杏达莫联合前列腺素E1治疗糖尿病并发外周动脉疾病的临床研究[J].中国基层医药, 2010, 17(z2):81-82.
10. Kroeze WK, Kristiansen K, Roth BL.Molecular biology of serotonin receptors structure and function at the molecular level[J].Curr Top Med Chem, 2002, 2(6):507-528.
11. 陈洁,叶志东,樊雪强,等.盐酸沙格雷酯用于股腘动脉长段闭塞介入治疗效果及安全性分析[J].心肺血管病杂志, 2013, 32(1):7-9.
12. 邵壮,顾洪斌,王志鸿,等.盐酸沙格雷酯对糖尿病伴膝下动脉病变球囊扩张成形术后疗效的影响[J].心肺血管病杂志, 2013, 32(1):16-19.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Clinical Efficacy of Sarpogrelate Hydrochloride in Preventing Restenosis after Femoral Artery Stent Implantation

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content